

#### Sexually Transmitted Infections in Indiana

Ariel Cheatham, MPH STI Epidemiologist

August 8, 2024



- Overview of the HIV/STI/Viral Hepatitis Division at IDOH
- What are reportable STIs
- How to report STIs



# IDOH HIV/STI/Viral Hepatitis Division

- Prevention
- Surveillance
- Services
- CQM/CI




# **Disease Intervention Specialists**

- State and Local DIS are trained in contact tracing, case investigation, and partner services to prevent and control the spread of infectious diseases (primarily, HIV and STIs).
- DIS offer:
  - HIV/STI prevention counseling
  - Testing
  - Partner services and referrals
  - Connection to care and social resources



### **Disease Intervention Specialists**

#### Map current as of June 2024 Link: <u>Disease Intervention Specialist</u> <u>Contact Map</u>





# **Reportable STIs in Indiana**

- Chancroid
- Chlamydia
- Gonorrhea & Disseminated Gonococcal Infection (DGI)
- Antibiotic Resistant Gonorrhea
- Syphilis (Adult & Congenital)

Mpox (formerly known as Monkeypox)



# Chlamydia

**Caused by Chlamydia trachomatis** 

- Can be asymptomatic
- **Common symptoms:** penile/vaginal discharge, dysuria, testicular swelling, rectal pain/bleeding/discharge

**Current treatment recommendation:** Doxycycline 100mg PO, BID x 7 days\*

If untreated, infected females may develop Pelvic Inflammatory Disease (PID)


\*for alternatives, see <u>2021 CDC STI treatment guidelines</u>



# Chlamydia

- 34,156 cases in 2022
- 33,690 cases in 2023\*

#### 2022 Indiana Rates





### Gonorrhea

#### Caused by Neisseria gonorrhoeae

- Often asymptomatic
- Common symptoms: penile/vaginal discharge, dysuria, vaginal bleeding between periods, testicular swelling, rectal itching/soreness/bleeding, sore throat, swollen lymph nodes

**Only ONE CDC recommended treatment:** Ceftriaxone 500mg IM in single dose for patients weighing < 150kg (1g appropriate for patients over 150kg)

If untreated, infected females may develop Pelvic Inflammatory Disease (PID)



#### **Antimicrobial Resistance**

#### We have **one class of drugs** left to treat gonorrhea!

# **SURRG/CARGOS** monitors trends in Indiana






Figure: Neisseria gonorrhoeae — Prevalence of Tetracycline, Penicillin, or Ciprofloxacin Resistance or Elevated Cefixime, Ceftriaxone, or Azithromycin Minimum Inhibitory Concentrations (MICs), by Year — Gonococcal Isolate Surveillance Project (GISP), 2000–2019. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2019. Atlanta: U.S. Department of Health and Human Services; 2021. 10

### **Disseminated Gonococcal Infections (DGI)**

- *N. gonorrhoeae* invades **bloodstream and spreads** to distinct sites in the body
- **Very Rare** estimated to occur in approximately 0.5-3.0% of gonorrhea infections; reportable, *effective* January 2023.
- **Mysterious** prevalence still unknown; however, number of cases seem to be increasing especially in the Midwest.
- Cluster of **Highly Related** DGI Southwest Michigan, 2019
  - Risk factors: Drug use, particularly methamphetamine

#### **Manifestations:**

- Septic arthritis
- Myositis
- Tenosynovitis
- Osteomyelitis
- Mitral valve endocarditis



### What clinicians can do...

**Report any DGI case** (lab confirmed or clinically suspected) to state health departments/STI program, per local protocols

Obtain **NAAT** <u>and</u> culture specimens at all exposed anatomic sites for patients with suspected DGI

# Ensure *N. gonorrhoeae* DGI isolates are submitted to local or state labs


• Isolates can be forwarded to CDC for additional testing



### Gonorrhea

- 12,520 cases in 2022
- 9,880 cases in 2023\*

#### 2022 Indiana Rates





# **Syphilis**

#### Caused by Treponema pallidum

4 Stages: Primary, Secondary, (Early/Late) Latent, Tertiary Additional complications: Neuro, otic, ocular

#### **Current treatment recommendation:**

- Primary, Secondary & Early Latent: Benzathine Penicillin G, 2.4 million units, IM\*
- <u>Late Latent & Tertiary</u>: Benzathine Penicillin G, 7.2 million units, IM in 3 doses 1 week apart each\*

**Congenital Syphilis:** infection passed from mother to unborn baby during pregnancy

\*for alternatives, see 2021 CDC STI treatment guidelines





Stage	Symptoms
Primary	Single or multiple chancres, typically small, firm, round and painless at infection site
Secondary	<ul> <li>Rough, red or brown spotted rash present on palms of hands, bottoms of feet, or trunk</li> <li>Mucosal lesions</li> <li>Fever, swollen lymph nodes, sore throat, weight loss, headache, fatigue, and muscle ache</li> </ul>
Latent	No symptoms
Tertiary	Cognitive, cardiovascular & neurological* symptoms are possible

\*Neurological, otic and ocular manifestations of syphilis can occur at any stage of infection



# Syphilis


- 2,121 cases in 2022
- 2,291 cases in 2023\*
- Notable increase in women of childbearing age (15-44)
- 38 cases of congenital syphilis reported in 2022
  - Preliminary reports of 50 cases in 2023

Syphilis Data Dashboard (data are preliminary)

Congenital and Adult Syphilis Toolkit



#### 2022 Indiana Rates



### Reporting STIs: CDR, 2015

#### Indiana Communicable Disease Rule, 2015

In Indiana, cases of **chancroid**, **chlamydia**, **gonorrhea**, **syphilis**, **and congenital syphilis** are required to be reported to the health department in your area **within one business day of diagnosis**; healthcare providers should not report cases of herpes or trichomoniasis.



### **Case Report Form**

#### Reporting a Case:

- Indiana Confidential Sexually Transmitted Disease Report State Form <u>56459</u> by fax to local STI District (see DIS Contact Map)
- Online Reporting via disease-specific RedCap survey

#### IDOH STI Surveillance webpage



# **Questions?**

#### **CONTACT**:

#### Ariel Cheatham, MPH

acheatham@health.in.gov

